Skip to main content
Premium Trial:

Request an Annual Quote

Edico Genome Collaborates with Intel on Computer Processors for NGS Data Analysis

NEW YORK (GenomeWeb) – Edico Genome today announced a collaboration with Intel that it believes will create better next-generation sequencing data analysis products incorporating Intel's Xeon computer chips. 

La Jolla, Calif.-based Edico Genome aims to create a cloud-based data analysis platform that can handle large data sets, including population-scale genomic data, while still maintaining accuracy and efficiency, the firm said in a statement.

"Across industries, the demands of big data are pushing the limits of general purpose processing, creating an opportunity for optimized solutions that are able to keep up with specific data processing demands," Ketan Paranjape, Intel general manager for life sciences, said in a statement. "As the use of NGS grows, many of our customers, including hospitals and research institutions, have a need for solutions that can process and analyze these huge data sets rapidly and cost effectively."

Edico Genome's Dragen processor is a computer chip pre-loaded with algorithms for NGS data analysis that the firm's CEO, Pieter van Rooyen, indicated would be featured in the Intel collaboration. When combined, the Edico and Intel technologies can analyze a whole genome in approximately 20 minutes, the firm said; the collaboration aims to enable that analysis in real time. 

Van Rooyen added that the partnership would help introduce the firm's Dragen processor to Intel's existing life sciences customer base, increasing adoption of the technology.

In 2014, Intel collaborated with the Broad Institute to optimize the Genome Analysis Toolkit for Xeon-powered servers, cutting the time required to analyze a whole human genome from three days to one, Edico Genome noted.

Molecular diagnostics firm Sequenom last year adopted Edico Genome's Dragen processor for non-invasive prenatal testing data analysis.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.